161922-40-3
161922-40-3
Chemical Structure
Acivicin hydrochloride
Synonym(s): AT-125 hydrochloride; U-42126 hydrochloride
- CAS No.: 161922-40-3
- Formula:C5H8Cl2N2O3
- Molecular Weight:215.03
IUPAC Name: (S)-2-amino-2-((S)-3-chloro-4,5-dihydroisoxazol-5-yl)acetic acid hydrochloride
InChIKey: IXBPTDHBIYEQHX-QYEIVYHBSA-N
SMILES: [H]Cl.ClC1=NO[C@@]([C@H](N)C(O)=O)([H])C1
Biological Activity: Acivicin hydrochloride (AT-125 hydrochloride), a natural product produced by Streptomyces sviceus, is a γ-glutamyl transpeptidase (GGT) inhibitor. Acivicin hydrochloride can across the blood-brain barrier and has anti-cancer, anti-parasitic properties[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Acivicin hydrochloride | 99.12% | Acivicin hydrochloride (AT-125 hydrochloride), a natural product produced by Streptomyces sviceus, is a γ-glutamyl transpeptidase (GGT) inhibitor. Acivicin hydrochloride can across the blood-brain barrier and has anti-cancer, anti-parasitic properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acivicin hydrochloride (Standard) | ≥98% | Acivicin (hydrochloride) (Standard) is the analytical standard of Acivicin (hydrochloride). This product is intended for research and analytical applications. Acivicin hydrochloride (AT-125 hydrochloride), a natural product produced by Streptomyces sviceus, is a γ-glutamyl transpeptidase (GGT) inhibitor. Acivicin hydrochloride can across the blood-brain barrier and has anti-cancer, anti-parasitic properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kreuzer J, et al. Target discovery of acivicin in cancer cells elucidates its mechanism of growth inhibition. Chem Sci. 2014 Dec 1;6(1):237-245. Epub 2014 Sep 26. [Content Brief]
- [2]. Chikhale EG, et al. Carrier-mediated transport of the antitumor agent acivicin across the blood-brain barrier. Biochem Pharmacol. 1995 Mar 30;49(7):941-5. [Content Brief]
